What does SS-31 actually do inside a cell?

SS-31 travels into the mitochondria — the cell's energy factories — and binds to a membrane fat called cardiolipin. This stabilises the membrane, reduces the build-up of harmful reactive oxygen species (molecular 'rust'), and helps mitochondria maintain their structure and energy output. Research suggests it does not interfere with healthy, normally functioning mitochondria.[2][6]

Is SS-31 the same as elamipretide?

Yes. SS-31 and elamipretide are the same compound — just different names. 'SS-31' is the research shorthand used in most laboratory studies, while 'elamipretide' is the name used in pharmaceutical and clinical development contexts. You will see both names in the scientific literature referring to the identical peptide molecule.[3]

Has SS-31 been tested in humans?

Most published research on SS-31 is preclinical, meaning it has been done in cell cultures and animal models. Some early human trials have been initiated, particularly in heart and kidney conditions, and a 2022 review noted emerging clinical evidence for kidney disease. However, large-scale human trials confirming efficacy and long-term safety have not yet been completed.[2]

Why do researchers find SS-31 interesting across so many different diseases?

Because mitochondrial dysfunction is a common thread in many serious conditions — heart disease, kidney failure, neurological decline, and lung disease all involve damaged or underperforming mitochondria. Since SS-31 targets the mitochondria directly, researchers hypothesise it could be relevant wherever mitochondrial breakdown plays a role, making it a broad-spectrum research candidate.[1][3][4][5]

SS-31 Peptide: Mitochondria Research & Evidence

What Is SS-31?

SS-31 — you may also see it called elamipretide — is a short, synthetic peptide. A peptide is just a tiny chain of amino acids, the same building blocks that make up proteins. What makes SS-31 unusual is its address: it is specifically designed to travel straight into the mitochondria of a cell.

Mitochondria are the energy factories inside your cells. They produce the fuel your heart beats with, your brain thinks with, and your muscles move with. When mitochondria malfunction, things go wrong fast — and that dysfunction shows up in a surprising range of diseases.

SS-31 works by anchoring itself to a fat molecule inside the mitochondrial membrane called cardiolipin. Think of cardiolipin as the inner lining of the factory wall. SS-31 stabilises that lining, reduces the build-up of harmful reactive oxygen species (ROS — essentially molecular rust), and helps keep the energy assembly line running.^[6]

What Are Researchers Studying It For?

Heart Protection

One major research focus is the heart during ischemia-reperfusion injury — the damage that happens when blood flow is cut off and then restored, such as during a heart attack. Researchers found that combining SS-31 with another compound in a heart cell model reduced a damaging process called ferroptosis (iron-driven cell death) and helped preserve mitochondrial function in oxygen-deprived cells.^[1]

Separately, scientists studying diabetic cardiomyopathy — heart muscle damage linked to diabetes — found that SS-31 activated a protective enzyme inside mitochondria called mitoGPX4, reducing the same ferroptosis pathway in high-glucose cell models.^[5]

Kidney Disease

The kidneys are packed with mitochondria because filtering blood is extremely energy-intensive. A 2022 review summarised evidence from multiple animal and cell models showing that SS-31 reduced mitochondrial ROS production, prevented the collapse of the mitochondrial membrane, and showed benefits across several types of kidney disease — from acute kidney injury to diabetic nephropathy.^[2] The authors also noted early clinical data, though large human trials are still needed.

Brain and Memory

In a 2019 mouse study, researchers triggered inflammation and memory problems by injecting a bacterial toxin called lipopolysaccharide (LPS). Mice treated with SS-31 performed significantly better on memory tests. The peptide appeared to protect mitochondria in the hippocampus — the brain's memory hub — reduce inflammation, and even help rebuild the tiny branches (dendritic spines) that neurons use to talk to each other.^[3] The researchers suggested SS-31 could have relevance for conditions involving neuroinflammation.

Lung Fibrosis

Pulmonary fibrosis means the lungs slowly scar over and lose the ability to move oxygen. In a 2025 mouse study, animals given a fibrosis-inducing drug (bleomycin) showed significant lung damage — but mice that also received SS-31 had less scarring, better mitochondrial structure, lower levels of inflammatory proteins like TNF-α and IL-6, and less cell death in lung tissue.^[4]

What Does the Evidence Actually Show?

Here is the honest picture: the vast majority of SS-31 research is preclinical, meaning it has been conducted in cell cultures and animal models. These results are genuinely exciting to scientists because the effects appear consistent across very different organ systems — all pointing back to mitochondrial protection.

Heart cell and animal models show reduced oxidative damage and preserved cell viability.^[1][5]
Kidney models show reduced ROS and improved mitochondrial structure.^[2]
Brain models show improved memory, reduced inflammation, and preserved synaptic connections.^[3]
Lung models show reduced scarring and lower inflammatory markers.^[4]

Human clinical trials are ongoing in certain conditions, but the field is still in early stages. That means we cannot yet draw firm conclusions about safety or effectiveness in people from these preclinical results alone.

How Does It Target Mitochondria So Precisely?

Most drugs that try to reach mitochondria struggle — the mitochondrial membrane is a tough barrier. SS-31's secret is its alternating charge pattern: it carries electrical properties that let it slip through mitochondrial membranes without needing a special transporter. Once inside, it binds to cardiolipin and sets up shop right where the energy-production chain operates.^[6] Critically, studies suggest it does not disrupt healthy mitochondria — it appears to selectively intervene when things are going wrong.^[2]

Interested in Dosage Data?

If you are researching SS-31 further, our SS-31 dosage chart compiles the dosing protocols used across published preclinical studies in one place. You can also use our calculator to explore how study doses scale across different model parameters. All information on this site is for research and educational purposes only — not medical advice.

Sources

SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110.
SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. — Oxidative medicine and cellular longevity, 2022. PMID 35707274.
Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. — Journal of neuroinflammation, 2019. PMID 31747905.
SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in Mice. — PloS one, 2025. PMID 40299935.
New insight for SS‑31 in treating diabetic cardiomyopathy: Activation of mitoGPX4 and alleviation of mitochondria‑dependent ferroptosis. — International journal of molecular medicine, 2024. PMID 39364755.
Mitochondrial protein interaction landscape of SS-31. — Proceedings of the National Academy of Sciences of the United States of America, 2020. PMID 32554501.

SS-31 Peptide: The Mitochondria Protector Researchers Are Watching